rotigexole

Rotigexole is an EVA Pharma transdermal patch product developed for Parkinson's disease that appears to be a branded or local-name formulation of **rotigotine**, a non-ergoline dopamine agonist delivered continuously through the skin. Based on the supplied trial context, rotigexole is specifically the 8 mg/24 hour transdermal patch evaluated against Neupro for adhesiveness and safety, indicating it is intended as a patch formulation containing rotigotine rather than a distinct new active substance. Rotigotine acts primarily as an agonist at dopamine D3, D2, and D1 receptors, with additional activity at selected adrenergic and serotonergic receptors, and is used to improve motor symptoms in Parkinson's disease through continuous dopaminergic stimulation.

Brand names

Neupro

Other names

rotigexole